

Economic issues in the management of drug therapy in Germany

Inaugural-Dissertation

zur Erlangung des Grades Doctor oeconomiae publicae (Dr. oec. publ.)

an der Ludwig-Maximilians-Universität München

D 19

vorgelegt von

Dominik Pascal Rottenkolber

aus Rosenheim

Jahr: 2011

Referent: Prof. Dr. Reiner Leidl

Korreferent: Prof. Dr. Jonas Schreyögg

Promotionsabschlussberatung: 08.02.2012

Content

EXECUTIVE SUMMARY	VII
LIST OF ABBREVIATIONS AND ACRONYMS	IX
LIST OF FIGURES AND TABLES	XIV
1. INTRODUCTION	1
2. OUTLINE OF THIS BOOK	8
2.1 INTRODUCTION	8
2.1.1 Terminology	8
2.1.2 Drug-related problems	12
2.2 CURRENT RESEARCH	13
2.2.1 Adverse drug reactions in Germany: direct costs of internal medicine hospitalizations	13
2.2.2 Drug-induced blood consumption: the impact of adverse drug reactions on demand for blood components in German departments of internal medicine	15
2.2.3 Costs of adverse drug events in German hospitals—a micro-costing study	18
2.2.4 Risk-sharing agreements—a new paradigm in German pharmaceutical reimbursement?	19
2.2.5 Financial incentives for improving drug adherence—bonuses and penalties	21
2.2.6 Structure of this thesis	24
3. ADVERSE DRUG REACTIONS IN GERMANY: DIRECT COSTS OF INTERNAL MEDICINE HOSPITALIZATIONS	26
ABSTRACT	26
3.1 BACKGROUND	27
3.2 METHODS	27
3.3 RESULTS	30
3.4 DISCUSSION	36
3.5 CONCLUSION	42
3.6 APPENDIX—SUPPLEMENTARY CONTENT	43
4. DRUG-INDUCED BLOOD CONSUMPTION: THE IMPACT OF ADVERSE DRUG REACTIONS ON DEMAND FOR BLOOD COMPONENTS IN GERMAN DEPARTMENTS OF INTERNAL MEDICINE ..	48
ABSTRACT	48
4.1 INTRODUCTION AND BACKGROUND	49
4.2 METHODS	50
4.3 RESULTS	52
4.4 DISCUSSION	55
4.5 CONCLUSION	58
4.6 APPENDIX—PRICES	59
5. COSTS OF ADVERSE DRUG EVENTS IN GERMAN HOSPITALS—A MICRO-COSTING STUDY	61
ABSTRACT	61
5.1 INTRODUCTION	62
5.2 METHODS	62
5.3 RESULTS	65
5.4 DISCUSSION	68
5.5 CONCLUSION	70

6. RISK-SHARING AGREEMENTS—A NEW PARADIGM IN GERMAN PHARMACEUTICAL REIMBURSEMENT?	73
ABSTRACT	73
6.1 INTRODUCTION	74
6.2 METHODS	75
6.3 THE RISK-SHARING APPROACH	75
6.3.1 Guarantees and warranties	78
6.4 RISK-SHARING AGREEMENTS IN THE CONTEXT OF NEW INSTITUTIONAL ECONOMICS	80
6.4.1 Principal-agent theory	80
6.4.2 Transaction costs	85
6.5. FRAMEWORK FOR THE EVALUATION OF RISK-SHARING AGREEMENTS	87
6.5.1 Criteria for the evaluation of risk-sharing agreements	87
6.5.2 Applying the framework on selected risk-sharing agreements	89
6.6 DISCUSSION	95
6.7 CONCLUSION	99
7. FINANCIAL INCENTIVES FOR IMPROVING DRUG ADHERENCE—PART 1: BONUSES	102
ABSTRACT	102
7.1 INTRODUCTION	103
7.2 METHODS	104
7.3 RESULTS	106
7.4 DISCUSSION	120
7.5 CONCLUSION	124
7.6 APPENDIX—QUALITY ASSESSMENT OF ALL INCLUDED STUDIES	125
8. FINANCIAL INCENTIVES FOR IMPROVING DRUG ADHERENCE—PART 2: PENALTIES	129
ABSTRACT	129
8.1 INTRODUCTION	130
8.2 METHODS	131
8.3 RESULTS	131
8.4 DISCUSSION	137
8.5 CONCLUSION	140
9. GENERAL DISCUSSION	142
9.1 FUTURE RESEARCH	142
9.1.1 Adverse drug events	142
9.1.2 Risk-sharing agreements	148
9.1.3 Adherence	149
9.2 GENERAL LIMITATIONS	151
9.2.1 Limitations in research on adverse drug events	151
9.2.2 Limitations in research on risk-sharing agreements	155
9.2.3 Limitations in research on drug non-adherence	156
9.3 MANAGERIAL IMPLICATIONS	156
10. GENERAL CONCLUSIONS	159
BIBLIOGRAPHY	164
CURRICULUM VITAE	193